Compare BMR & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMR | BCTX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 28.8M |
| IPO Year | 2021 | 2025 |
| Metric | BMR | BCTX |
|---|---|---|
| Price | $1.43 | $4.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 77.1K | ★ 202.7K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $0.61 |
| 52 Week High | $4.32 | $14.68 |
| Indicator | BMR | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 52.04 |
| Support Level | N/A | $4.10 |
| Resistance Level | $1.94 | $4.51 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 36.89 | 64.61 |
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.